Objective: Second-line treatment with paclitaxel and carboplatin enhances survival of women with platinum-sensitive recurrent ovarian cancer (ROC). However, because of its cumulative neurotoxicity, there is a strong demand for platinum-combinations with better therapeutic index. Because of its pharmacological properties, topotecan is a good adjunct to carboplatin in this setting, but its safety and efficacy remains to be defined.
Methods: Patients with platinum-sensitive ROC were eligible in this multicenter phase I/II study, stratified according to treatment-free interval (TFI). Dose level 0 consisted of topotecan 1 mg/m(2)/d1-3/q21d plus carboplatin AUC5/d3/q21d. DLT was defined as grade > or =3 neutropenia or thrombocytopenia or grade > or =3 non-hematological toxicity excluding alopecia, nausea and vomiting, accompanied by a treatment delay >1 week.
Results: From June 2004 to August 2005, 26 patients were enrolled, receiving a total of 145 cycles of chemotherapy. MTD was reached at topotecan 0.75 mg/m(2) and carboplatin AUC5. We observed a single grade 4 leucopenia. There were 3 (12%), 15 (58%) and 8 (31%) events of grade 3/4 hematological anaemia, leucopenia, and thrombocytopenia. Response rate was 67% (95% CI 43-85), median progression-free survival 9.5 months (95% CI 7.3-12.0), median overall survival 19.4 months (95% CI 12.3-26.9). None of the toxicity or efficacy endpoints were associated with TFI.
Conclusion: Topotecan and carboplatin is a well tolerated novel doublet option for women with platinum sensitive ROC. We encourage further studies on this approach, but to limit the doses of topotecan to 0.75 mg/m(2)/d1-3 and carboplatin AUC 5/d3.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-007-0617-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs.
Invest Ophthalmol Vis Sci
December 2024
Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Purpose: Refractory or recurrent retinoblastoma results from acquired chemoresistance and the management of these eyes often requires surgical removal. Our objective was to develop retinoblastoma models resistant to chemotherapy by exposing cancer cells to repeated chemotherapy mimicking the clinical scenario. These newly resistant cells were used to evaluate potential novel therapies.
View Article and Find Full Text PDFSingle- Versus Triple-Agent Intra-Arterial Chemotherapy for Retinoblastoma.
Am J Ophthalmol
January 2025
From the Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children (N.O.A., K.C., A.M., B.L.G., S.N.K.), Toronto, Canada; Department of Ophthalmology and Vision Sciences, University of Toronto (N.O.A., A.M., B.L.G., S.N.K.), Toronto, Canada. Electronic address:
Article Synopsis
- The study aimed to compare outcomes of single-agent (melphalan) versus triple-agent (melphalan, topotecan, carboplatin) intra-arterial chemotherapy for retinoblastoma (RB) in children, focusing on eye salvage.
- Researchers reviewed cases of 37 children under 18 who underwent intra-arterial chemotherapy from 2016 to 2024, analyzing complications, tumor responses, and survival rates.
- Results showed that the triple-agent therapy had a higher rate of partial or complete tumor response (91% vs. 62%), but ocular complications were similar between both groups (31% single-agent vs. 52% triple-agent).
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Ther Adv Med Oncol
September 2024
Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Article Synopsis
- Second-line treatment for small-cell lung cancer (SCLC) typically depends on how long it's been since the last platinum therapy, with carboplatin and etoposide showing better results if the interval is over 90 days, but this study looks at its effectiveness post-chemo-immunotherapy.
- A retrospective review of 93 patients who received this rechallenge after initial chemo-immunotherapy revealed a 59.1% overall response rate, with a median progression-free survival of 5 months and overall survival of 7 months.
- The findings indicate that carboplatin and etoposide remain a valid second-line option for extensive-stage SCLC, providing consistent outcomes regardless of the platinum-free interval as long as it exceeds
What have we learned about intraarterial chemotherapy (Ophthalmic Artery Chemosurgery) for retinoblastoma in the past 18 years? The third A. Linn Murphree Lecture.
Ophthalmic Genet
December 2024
Department of Surgery, Memorial Sloan Kettering Cancer Center Ringgold Standard Institution, New York, New York, USA.
Intraarterial chemotherapy (Ophthalmic Artery Chemosurgery/OAC) for retinoblastoma has transformed management of retinoblastoma worldwide since Pierre Gobin MD and I introduced it in 2006. Case reports, institutional series, meta-analyses, and randomized trials have validated its effectiveness and safety. It allows more eyes to be saved (at Memorial Sloan Kettering Cancer Center (MSKCC) as a result, we have gone from removing 96% of retinoblastoma eyes that presented with leukocoria (comparable to modern day International Classification "D" and "E" eyes) to saving 95% of these eyes with primary OAC management allows the majority of advanced intraocular eyes to be salvaged (both "D" and "E" eyes) prior to the chemoreduction era to saving 95% of these eyes with primary OAC management.
View Article and Find Full Text PDFExpert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
Rev Colomb Obstet Ginecol
June 2024
Instituto Nacional de Cancerología, Bogotá, Colombia.
Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time with the advent of new therapies and multimodal strategies. The objective of this consensus of experts is to generate national recommendations for the profiling and management of advanced or metastatic high-grade OEC, defined as stages III and IV of the “The International Federation of Gynecology and Obstetrics (FIGO) classification at the time of diagnosis to base on the literature review that included international evidence-based clinical practice guidelines (CPG). Material and methods: Eleven panelists (oncologists and gynecological oncologists) answered 8 questions about the profiling and management of advanced or metastatic ovarian epithelial carcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!